Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen
CancerPublished 15 August 1996Open access
Gerald P. Murphy, Robert J. Barren, Sheila J. Erickson, Victoria Bowes, Robert L. Wolfert, Georg Bartsch
Citations64
SJR quartileQ1
SJR score2.95
SNIP1.90
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This report summarizes a prospective two‐year multicenter test of the new prostate cancer markers, free‐prostate specific antigen (f‐PSA) and prostate specific membrane antigen (PSMA), of their diagnostic or prognostic capabilities.
Abstract
These data suggest that f-PSA values do not provide additional diagnostic benefit compared with total PSA in screening populations, in the presence of suspected cancer, postprostatectomy, or in metastatic disease. PSMA is of prognostic significance, especially in the presence of metastatic disease, and correlates well with the stage of disease in cancers detected in a screened population.
Keywords
Medicine
Seminars in Nuclear MedicineBasic principles of ROC analysis
5,991 Citations1978Charles E. Metz
ROC analysis is shown to be related in a direct and natural way to cost/benefit analysis of diagnostic decision making and the concepts of "average diagnostic cost" and "average net benefit" are developed and used to identify the optimal compromise among various kinds of diagnostic error.
PubMedA complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
939 Citations1991Ulf‐Håkan Stenman, Jari Leinonen +4 more
The proportion of the PSA-alpha 1-antichymotrypsin complex was higher in patients with prostatic cancer than in those with benign hyperplasia, and assay of the complex had a higher sensitivity for cancer than assay of total PSA immunoreactivity.
Clinical ChemistryProstate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
932 Citations1991Hans Lilja, Anders Christensson +5 more
To characterize the PSA immunoreactivity in serum, monoclonal antibodies produced against PSA and a polyclonal rabbit IgG against alpha 1-antichymotrypsin were used in the design of three noncompetitive PSA assays and an immunoreactive 25- to 40-kDa compound was the minor fraction.
The Journal of UrologyPurification of a Human Prostate Specific Antigen
830 Citations2016M.C. Wang, Luis Valenzuela +2 more
This report presents the first demonstration of the purification of a prostate‐specific antigen that does not represent prostatic acid phosphatase and shows a single protein band on analytical polyacrylamide gel electrophoresis and isoelectric focusing.
JAMAEvaluation of Percentage of Free Serum Prostate-Specific Antigen to Improve Specificity of Prostate Cancer Screening
685 Citations1995William J. Catàlona
Measurement of percentage of free PSA in serum improves specificity of prostate cancer screening in selected men with elevated total serum PSA levels and can reduce unnecessary prostate biopsies with minimal effects on the cancer detection rate; however, further studies are needed to define optimal cutoffs.
UrologyMeasurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen
291 Citations1995Albert A. Luderer, Ya-Ting Chen +9 more
Measurement of the free PSA level in a patient's serum and calculation of the proportion of free to total PSA enhances the ability to distinguish benign histologic conditions from cancer while retaining high sensitivity for detecting cancer in men who present with total PSC levels between 4.0 and 10.0 ng/mL.
The LancetSerum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer
271 Citations1994U-H Stenman, J. Leinonen +4 more
The results suggest it is advisable to confine screening for prostate cancer to men with a life expectancy of clearly more than 10 years--ie, younger men, who have the greatest chance to benefit from early detection.
1993 (2nd) International Symposium on Uncertainty Modeling and AnalysisReceiver operating characteristic laboratory (ROCLAB): Software for developing decision strategies that account for uncertainty
211 Citations2002J.M. DeLeo
ROCLAB is a public domain software package written in Microsoft QuickBASIC for PC microprocessors that computes ROC functions and their useful derived features for discrete and fuzzy class membership data.
UrologyThe value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men
110 Citations1995Chris H. Bangma, Ries Kranse +2 more
The F/T ratio increased the specificity of total serum PSA in the PSA range between 4.0 and 10.0 ng/mL, but this improved specificity was not significant, nor for gland volumes restricted to 50 mL or less.
CancerThe results of a five-year early prostate cancer detection intervention
108 Citations1996Curtis Mettlin, Gerald P. Murphy +9 more
The American Cancer Society‐National Prostate Cancer Detection Project (ACS‐NPCDP) is a multidisciplinary evaluation of early prostate cancer detection interventions.
Urologic Clinics of North AmericaCriteria for Evaluating Patient Responses to Treatment Modalities for Prostatic Cancer
85 Citations1984Nelson H. Slack, Gerald P. Murphy
Criteria for evaluating response to therapy for both early and late stages of prostate cancer, as developed by the National Prostatic Cancer Project, are presented and discussed.
UrologyThe value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density
81 Citations1995Chris H. Bangma, Ries Kranse +2 more
The most cost-effective protocol for screening prostate carcinoma appears to be prescreening by total serum PSA, with the F/T ratio used to detect carcinomas in the PSA range below 4.0 ng/mL, but the best threshold remains to be assessed.
PubMedComparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.
70 Citations1995G.P. Murphy, Haakon Ragde +8 more
The elevated PSMA levels predicted a state of clinical progression or clinical resistance in most cases and were of better prognostic value than PSA levels in this study.
The ProstateWestern blot assay for prostate‐specific membrane antigen in serum of prostate cancer patients
57 Citations1994Yvan Rochon, Julius S. Horoszewicz +6 more
Analysis of studies aimed at identifying PSM in the serum of normal and benign prostatic hyperplasia donors and patients with adenocarcinoma of the prostate suggests that the development of an assay utilizing the PSM and new monoclonal antibodies directed against the antigen, could provide a feasible test for prostatic cancers.
The ProstateComparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP‐based enzyme‐linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement
50 Citations1995Gerald P. Murphy, Eric H. Holmes +5 more
The ELISA and PSM results may be assessing a different clinical response to prostatic cancer than that recognized by PSA, and a secondary generation of monoclonal antibodies to PSM is being developed.
Journal of Surgical OncologyEffect of exogenous testosterone replacement on prostate‐specific antigen and prostate‐specific membrane antigen levels in hypogonadal men
41 Citations1995Thomas H. Douglas, Roger R. Connelly +4 more
It is suggested that in hypogonadal men, neither PSMA nor PSA expression is testosterone‐dependent, and both levels are likely to reflect hormonal or clonal resistance or an independence with respect to testosterone regulation.
The ProstateMeasurement of prostate-specific membrane antigen in the serum with a new antibody
37 Citations1996G.P. Murphy, William T. Tino +9 more
This report confirms the presence of the monoclonal antibody 3F5.4G6, which reacts with the extracellular domain of PSMA, and indicates that these two antibodies are well suited for use in a sandwich immunoassay, either one as a capture or detection antibody.
Journal of Clinical Laboratory AnalysisCorrelation of serum concentrations of psa‐act complex with total psa in random and serial specimens from patients with bph and prostate cancer
27 Citations1995James T. Wu, Lorraine Wilson +3 more
CancerThe second Stanford conference on International Standardization of prostate specific antigen assays
19 Citations1995Gerald P. Murphy
The first scientific presentation was made by Dr. Thomas Stamey, Chairman of the Department of Urology, and host of the conference, addressing the important issues in prostatic physiology, particularly those associated with the clinical presence of serum PSA values between 4.0 and 10.0 ng/ml.
Annals of Clinical Biochemistry International Journal of Laboratory MedicineDisagreement between the Roche Cobas® Core and Hybritech TANDEM®-E PSA Assays When Measuring Free, Complexed and Total Serum Prostate Specific Antigen
7 Citations1994C R Tillyer, Monique C.P. Konings +2 more
It is possible that the adoption of a universal standard for PSA will not completely resolve the disagreement between PSA assay on individual patient samples, and the use of separate assays for the free and complexed forms may be necessary for the further clinical development of PSA as a tumour marker.